Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-02-10 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' as of January 31, 2023. This content details the total number of shares and voting rights, which is a specific regulatory disclosure often required monthly in certain jurisdictions (like France, referencing the AMF). This type of disclosure is not covered by the specific codes like 10-K, ER, or IR. It is a periodic regulatory update concerning share capital structure and voting power, which fits best under the general 'Regulatory Filings' (RNS) category as a specific, recurring disclosure that doesn't match the other specialized types (like DVA for results, or SHA for a capital change event). Given the structure and content, RNS is the most appropriate fallback for this specific monthly regulatory disclosure.
2023-02-10 English
Ipsen presents strong full-year 2022 results and guidance for 2023
Earnings Release Classification · 1% confidence The document is titled "Ipsen presents strong full-year 2022 results and guidance for 2023" and contains detailed financial tables comparing FY 2022 results to FY 2021, including Total Sales, Operating Income, and EPS. It also provides CEO commentary on the year's performance and financial guidance for FY 2023. This content structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, often containing key highlights and summary tables before a more comprehensive filing like the 10-K. Although it contains audited statements information, the primary focus and presentation style align with an ER rather than a full 10-K or a standalone Audit Report (AR). It is not a transcript (CT), presentation (IP), or a simple announcement of a report publication (RPA). FY 2022
2023-02-09 English
Ipsen présente de solides résultats pour l’année 2022 et ses objectifs financiers pour 2023
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and presents "solides résultats pour l'année 2022 et ses objectifs financiers pour 2023" (solid results for the year 2022 and its financial targets for 2023). It contains key financial highlights (sales, operating margin, EPS) for the full year 2022, management commentary, and forward-looking guidance for 2023. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, typically released before the full, detailed report (like a 10-K or IR). Although it mentions the consolidated financial statements have been audited and the auditor's report is being published, the document itself is the summary announcement, not the full report or the audit report itself. It is not a transcript (CT) or a formal regulatory filing like a 10-K. Therefore, the most appropriate classification is Earnings Release (ER). FY 2022
2023-02-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated January 27, 2023, announcing that Ipsen's investigational drug, palovarotene, received a negative opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding marketing authorization in the E.U. It discusses clinical trial data (MOVE trial), regulatory processes (EMA, FDA), and the company's commitment to seeking re-examination. This content is characteristic of a corporate announcement regarding regulatory or clinical development milestones, which is typically disseminated via an Earnings Release (ER) if it contains key financial/operational news, or sometimes as a Regulatory Filing (RNS) if it's purely regulatory. Given that it details a significant regulatory decision and includes management commentary and context about the disease and trial, it functions as an immediate public disclosure of material information. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a presentation (IP), the most fitting category for a material, time-sensitive announcement of this nature, especially one concerning regulatory outcomes, is the Earnings Release (ER), as these releases often cover key operational and regulatory news outside of scheduled earnings calls. It is not a short announcement pointing to another document, so RPA/RNS is less likely than ER.
2023-01-27 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 27, 2023, issued by Ipsen, detailing a regulatory decision from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the drug palovarotene for FOP. It discusses the negative opinion received, Ipsen's intention to request a re-examination, and provides extensive background on the disease (FOP), the clinical trial (MOVE), and the drug itself. This content structure—a formal announcement of a regulatory outcome, including scientific context and next steps—is characteristic of a press release announcing significant corporate or regulatory news. Since it is not a full annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a transcript (CT), and it is not merely announcing the publication of another document (RPA), the most appropriate classification is a general Regulatory Filing (RNS) or potentially an announcement related to legal/regulatory matters. Given the focus on a specific regulatory opinion (CHMP/EMA) and the company's response, it fits best under the general regulatory announcement category, RNS, as it is a formal communication to the market about a regulatory event, rather than a specific financial report type.
2023-01-27 French
News releases during takeover bids / Takeover bids Other news releases
M&A Activity Classification · 1% confidence The document is a press release announcing that Ipsen will acquire Albireo. The content details the terms of the acquisition (cash tender offer, CVR), the strategic rationale (strengthening Rare Disease portfolio with Bylvay), and transaction details. This type of announcement, concerning a merger or takeover proposal, directly corresponds to the 'M&A Activity' definition. Keywords supporting this classification include: 'acquire Albireo', 'definitive merger agreement', 'cash tender offer', 'acquisition', and 'Transaction details'. This is not an Earnings Release (ER) as it focuses on M&A, not periodic financial results highlights. It is not a Call Transcript (CT) or an Investor Presentation (IP). It is clearly a corporate action announcement related to a takeover/merger, fitting the TAR code.
2023-01-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.